Review Article
Tailored Extracellular Vesicles: Novel Tool for Tissue Regeneration
Table 4
Modified EVs in the therapy of cardiovascular related diseases.
| Diseases | EV Sources | Specific substrates | Modification methods | Modified EVs | Biological effects | Ref. |
| MI | hMSC | lncRNA KLF3-AS1 | Cell transfection | KLF3-AS1-EV | Antiapoptosis and pyroptosis | [89] | MI | BMSC | miR-210 | Cell transfection | miR210-EV | Antiapoptosis effects | [90] | MI | BMSC | GATA-4 | Cell transfection | GATA-4-EV | Antiapoptosis and promotion of cardiac function recovery | [99] | MI | CDC | CMP | Fuse targeted peptide with LAMP2B | CMP-EV | Higher cardiac EV retention; less apoptosis | [101] | MI | BMSC | Fe3O4-treated BMSCs | Magnetic particles; Extrusion | Mag-EM | Retention of EMs within infarcted heart; cardiac function recovery | [105] | MI | Rat serum | GMNPEC with anti-CD63 and anti-MLC antibody | Magnetic nanoparticles; antibody | GMNPEC–EV | Recruitment, transport, and targeted delivery of EVs; angiogenesis | [106] | MI | iCM | Hydrogel patch | Biomaterials | Patch-EV | Sustained delivery of EVs | [108] | AS | M2 Macrophage | HAL | Electroporation | HAL-EV | Excellent inflammation-tropism and anti-inflammation effects | [111] | AS | HucMSC | miR-145 | Cell transfection | miR-145-EV | Inhibition of cell migration and atherosclerotic plaque | [110] | AS | HucMSC | HucMSC | Improved extrusion methods | FT/EM | Higher production yield of FT/EM; anti-inflammation | [112] |
|
|